Effects of Δ9-THC on working memory: Implications for schizophrenia?

Primary Psychiatry

Volumn 16, Issue 4, 2009, Pages 51-59

  Vadhan, Nehal P ^a   Serper, Mark R ^b   Haney, Margaret ^a  

^a New York State Psychiatric Institute ^*  (United States)

^b HOFSTRA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRONABINOL;

CANNABIS ADDICTION; CANNABIS SMOKING; COGNITION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE PREDISPOSITION; HUMAN; MEMORY DISORDER; MENTAL PERFORMANCE; ONSET AGE; OUTCOME ASSESSMENT; REVIEW; RISK ASSESSMENT; SCHIZOPHRENIA; WORD RECOGNITION; WORKING MEMORY;

EID: 76749148114     PISSN: 10826319     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (79)

1. Raby WN. Comorbid cannabis misuse in psychotic disorders: treatment strategies. Primary Psychiatry. 2009;16(4):29-34.
2. Baddeley A. Working memory: looking back and looking forward. Nat Rev Neurosci. 2003;4(10):829-839.
3. Wechsler D. The Wechsler Adult Intelligence Scale. 3rd ed. San Antonio, TX: The Psychological Corporation; 1997.
4. Heaton RK. Wisconsin Card Sorting Test - Computer Version 4 - Research Edition - "English". 4.21 ed. San Antonio, TX: Psychological Corporation; 2005.
5. Shallice T. Specific impairments of planning. Philos Trans R Soc Lond B Biol Sci. 1982;298(1089):199-209.
6. Bechara A, Dolan S, Denburg N, Hindes A, Anderson SW, Nathan PE. Decision-making deficits, linked to a dysfunctional ventromedial prefrontal cortex, revealed in alcohol and stimulant abusers. Neuropsychologia. 2001;39(4):376-389.
7. Kyllonen PC, Christal RE. Reasoning ability is (little more than) working-memory capacity?! Intelligence. 1990;14(4):389-433.
8. Snitz BE, Curtis CE, Zald DH, Katsanis J, Iacono WG. Neuropsychological and oculomotor correlates of spatial working memory performance in schizophrenia patients and controls. Schizophr Res. 1999;38(1):37-50.
9. Park S, Puschel J, Sauter BH, Rentsch M, Hell D. Spatial working memory deficits and clinical symptoms in schizophrenia: a 4-month follow-up study. Biol Psychiatry. 1999;46(3):392-400.
10. Brebion G, Amador X, Smith MJ, Gorman JM. Memory impairment and schizophrenia: the role of processing speed. Schizophr Res. 1998;30(1):31-39.
11. Wexler BE, Stevens AA, Bowers AA, Sernyak MJ, Goldman-Rakic PS. Word and tone working memory deficits in schizophrenia. Arch Gen Psychiatry. 1998;55(12):1093-1096.
12. Dreher JC, Banquet JP, Allilaire JF, Paillere-Martinot ML, Dubois B, Burnod Y. Temporal order and spatial memory in schizophrenia: a parametric study. Schizophr Res. 2001;51(2-3):137-147.
13. Silver H, Feldman P, Bilker W, Gur RC. Working memory deficit as a core neuropsychological dysfunction in schizophrenia. Am J Psychiatry. 2003;160(10):1809-1816.
14. McClure MM, Bowie CR, Patterson TL, et al. Correlations of functional capacity and neuropsychological performance in older patients with schizophrenia: evidence for specificity of relationships? Schizophr Res. 2007;89(1-3):330-338.
15. Williams LM, Whitford TJ, Flynn G, et al. General and social cognition in first episode schizophrenia: identification of separable factors and prediction of functional outcome using the IntegNeuro test battery. Schizophr Res. 2008;99(1-3):182-191.
16. Serper MR, Beech DR, Harvey PD, Dill C. Neuropsychological and symptom predictors of aggression on the psychiatric inpatient service. J Clin Exp Neuropsychol. 2008;30:700-709.
17. Corcoran C, Whitaker A, Coleman E, et al. Olfactory deficits, cognition and negative symptoms in early onset psychosis. Schizophr Res. 2005;80(2-3):283-293.
18. Erlenmeyer-Kimling L, Rock D, Roberts SA, et al. Attention, memory, and motor skills as childhood predictors of schizophrenia-related psychoses: the New York High-Risk Project. Am J Psychiatry. 2000;157(9):1416-1422.
19. Goldman-Rakic PS. Working memory dysfunction in schizophrenia. J Neuropsychiatry Clin Neurosci. 1994;6(4):348-357.
20. Lewis DA, Moghaddam B. Cognitive dysfunction in schizophrenia: convergence of gamma-aminobutyric acid and glutamate alterations. Arch Neurol. 2006;63(10):1372-1376.
21. Gonzalez R, Carey C, Grant I. Nonacute (residual) neuropsychological effects of cannabis use: a qualitative analysis and systematic review. J Clin Pharmacol. 2002;42(11 suppl):48S-57S.
22. Lundqvist T. Cognitive consequences of cannabis use: comparison with abuse of stimulants and heroin with regard to attention, memory and executive functions. Pharmacol Biochem Behav. 2005;81(2):319-330.
23. Bolla KI, Brown K, Eldreth D, Tate K, Cadet JL. Dose-related neurocognitive effects of marijuana use. Neurology. 2002;59(9):1337-1343.
24. Verdejo-Garcia A, Benbrook A, Funderburk F, David P, Cadet J-L, Bolla KI. The differential relationship between cocaine use and marijuana use on decision-making performance over repeat testing with the Iowa Gambling Task. Drug Alcohol Depend. 2007;90(1):2-11.
25. Pope HG, Jr., Gruber AJ, Hudson JI, Huestis MA, Yurgelun-Todd D. Neuropsychological performance in longterm cannabis users. Arch Gen Psychiatry. 2001;58(10):909-915.
26. Schweinsburg AD, Nagel BJ, Schweinsburg BC, Park A, Theilmann RJ, Tapert SF. Abstinent adolescent marijuana users show altered fMRI response during spatial working memory. Psychiatry Res. 2008;163(1):40-51.
27. Jager G, Kahn RS, Van Den Brink W, Van Ree JM, Ramsey NF. Long-term effects of frequent cannabis use on working memory and attention: an fMRI study. Psychopharmacology (Berl). 2006;185(3):358-368.
28. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
29. Fowler IL, Carr VJ, Carter NT, Lewin TJ. Patterns of current and lifetime substance use in schizophrenia. Schizophr Bull. 1998;24(3):443-455.
30. Rosen JL, Miller TJ, D'Andrea JT, McGlashan TH, Woods SW. Comorbid diagnoses in patients meeting criteria for the schizophrenia prodrome. Schizophr Res. 2006;85(1-3):124-131.
31. Corcoran C, Kimhy D, Stanford A, et al. Temporal association of cannabis use with symptoms in individuals at clinical high risk for psychosis. Schizophr Res. 2008;106(2-3):286-293.
32. Moore TH, Zammit S, Lingford-Hughes A, et al. Cannabis use and risk of psychotic or affective mental heath outcomes: a systematic review. Lancet. 2007;370(9584):319-328.
33. Bodkin LL, Singh A, Corcoran C. Cannabis as a risk factor for psychosis in vulnerable teens: implications for treatment. Primary Psychiatry. 2008;15(6):51-57.
34. Degenhardt L, Hall W, Lynskey M. Testing hypotheses about the relationship between cannabis use and psychosis. Drug Alcohol Depend. 2003;71(1):37-48.
35. Caspi A, Moffitt TE, Cannon M, et al. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction. Biol Psychiatry. 2005;57(10):1117-1127.
36. Phillips LJ, Curry C, Yung AR, Yuen HP, Adlard S, McGorry PD. Cannabis use is not associated with the development of psychosis in an ultra high-risk group. Aust N Z J Psychiatry. 2002;36(6):800-806.
37. Coulston CM, Perdices M, Tennant CC. The neuropsychology of cannabis and other substance use in schizophrenia: review of the literature and critical evaluation of methodological issues. Aust N Z J Psychiatry. 2007;41(11):869-884.
38. Coulston CM, Perdices M, Tennant CC. The neuropsychological correlates of cannabis use in schizophrenia: lifetime abuse/dependence, frequency of use, and recency of use. Schizophr Res. 2007;96(1-3):169-184.
39. Verdoux H, Gindre C, Sorbara F, Tournier M, Swendsen JD. Effects of cannabis and psychosis vulnerability in daily life: an experience sampling test study. Psychol Med. 2003;33(1):23-32.
40. Kimhy D, Durbin K, Corcoran CM. Cannabis and psychosis: what can daily diaries tell us about who is vulnerable? Primary Psychiatry. 2009;16(4):44-48.
41. Ranganathan M, D'Souza DC. The acute effects of cannabinoids on memory in humans: a review. Psychopharmacology (Berl). 2006;188(4):425-444.
42. Haney M, Comer SD, Ward AS, Foltin RW, Fischman MW. Factors influencing marijuana self-administration by humans. Behav Pharmacol. 1997;8(2-3):101-112.
43. D'Souza DC, Perry E, MacDougall L, et al. The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology. 2004;29(8):1558-1572.
44. Haney M, Gunderson EW, Rabkin J, et al. Dronabinol and marijuana in HIV-positive marijuana smokers. Caloric intake, mood, and sleep. J Acquir Immune Defic Syndr. 2007;45(5):545-554.
45. Nordstrom BR, Hart CL. Assessing cognitive functioning in cannabis users: cannabis use history an important consideration. Neuropsychopharmacology. 2006;31(12):2798-2799.
46. Foltin RW, Capriotti RM, McEntee MA, Fischman MW, Brady JV, Pedroso JJ. Effects of marijuana, cocaine, and task performance on cardiovascular responsivity. NIDA Res Monogr. 1987;76:259-265.
47. Hart CL, van Gorp W, Haney M, Foltin RW, Fischman MW. Effects of acute smoked marijuana on complex cognitive performance. Neuropsychopharmacology. 2001;25(5):757-765.
48. Cherek DR, Lane SD, Dougherty DM. Possible amotivational effects following marijuana smoking under laboratory conditions. Exp Clin Psychopharmacol. 2002;10(1):26-38.
49. Ilan AB, Smith ME, Gevins A. Effects of marijuana on neurophysiological signals of working and episodic memory. Psychopharmacology (Berl). 2004;176(2):214-222.
50. Ilan AB, Gevins A, Coleman M, ElSohly MA, de Wit H. Neurophysiological and subjective profile of marijuana with varying concentrations of cannabinoids. Behav Pharmacol. 2005;16(5-6):487-496.
51. Lane SD, Cherek DR, Lieving LM, Tcheremissine OV. Marijuana effects on human forgetting functions. J Exp Anal Behav. 2005;83(1):67-83.
52. Fant RV, Heishman SJ, Bunker EB, Pickworth WB. Acute and residual effects of marijuana in humans. Pharmacol Biochem Behav. 1998;60(4):777-784.
53. Chait LD, Perry JL. Acute and residual effects of alcohol and marijuana, alone and in combination, on mood and performance. Psychopharmacology. 1994;115(3):340-349.
54. Heishman SJ, Huestis MA, Henningfield JE, Cone EJ. Acute and residual effects of marijuana: profiles of plasma THC levels, physiological, subjective, and performance measures. Pharmacol Biochem Behav. 1990;37(3):561-565.
55. Ramaekers JG, Kauert G, van Ruitenbeek P, Theunissen EL, Schneider E, Moeller MR. High-potency marijuana impairs executive function and inhibitory motor control. Neuropsychopharmacology. 2006;31(10):2296-2303.
56. Lane SD, Cherek DR, Tcheremissine OV, Lieving LM, Pietras CJ. Acute marijuana effects on human risk taking. Neuropsychopharmacology. 2005;30(4):800-809.
57. Vadhan NP, Hart CL, van Gorp WG, Gunderson EW, Haney M, Foltin RW. Acute effects of smoked marijuana on decision making, as assessed by a modified gambling task, in experienced marijuana users. J Clin Exp Neuropsychol. 2007;29(4):357-364.
58. Weinstein A, Brickner O, Lerman H, et al. A study investigating the acute dose - response effects of 13 mg and 17 mg {Delta} 9- tetrahydrocannabinol on cognitive - motor skills, subjective and autonomic measures in regular users of marijuana. J Psychopharmacol. 2008;22(4):441-451.
59. Bechara A, Martin EM. Impaired decision making related to working memory deficits in individuals with substance addictions. Neuropsychology. 2004;18(1):152-162.
60. Phillips LH, Wynn V, Gilhooly KJ, Della Sala S, Logie RH. The role of memory in the Tower of London task. Memory. 1999;7(2):209-231.
61. Lane SD, Yechiam E, Busemeyer JR. Application of a computational decision model to examine acute drug effects on human risk taking. Exp Clin Psychopharmacol. 2006;14(2):254-264.
62. Veale DM, Sahakian BJ, Owen AM, Marks IM. Specific cognitive deficits in tests sensitive to frontal lobe dysfunction in obsessive-compulsive disorder. Psychol Med. 1996;26(6):1261-1269.
63. Green MF, Kern RS, Braff DL, Mintz J. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"?. Schizophr Bull. 2000;26(1):119-136.
64. Powell DH. Comment on Computerized assessment of arithmetic computation skills with MicroCog. J Int Neuropsychol Soc. 1997;3(2):200.
65. Ramaekers JG, Kauert G, Theunissen EL, Moeller MR. Up in smoke: comparability of THC dosing across performance studies. Neuropsychopharmacology. 2006;31(12):2800-2801.
66. ElSohly MA, Ross SA, Mehmedic Z, Arafat R, Yi B, Banahan BF 3rd. Potency trends of delta9-THC and other cannabinoids in confiscated marijuana from 1980-1997. J Forensic Sci. 2000;45(1):24-30.
67. Piskulic D, Olver JS, Norman TR, Maruff P. Behavioural studies of spatial working memory dysfunction in schizophrenia: a quantitative literature review. Psychiatry Res. 2007;150(2):111-121.
68. Harvey PD, Serper MR, White L, et al. The convergence of neuropsychological testing and clinical ratings of cognitive impairment in patients with schizophrenia. Compr Psychiatry. 2001;42(4):306-313.
69. Vadhan NP, Serper MR, Harvey PD, Chou JC, Cancro R. Convergent validity and neuropsychological correlates of the schedule for the assessment of negative symptoms (SANS) attention subscale. J Nerv Ment Dis. 2001;189(9):637-641.
70. Basso MR, Nasrallah HA, Olson SC, Bornstein RA. Neuropsychological correlates of negative, disorganized and psychotic symptoms in schizophrenia. Schizophr Res. 1998;31(2-3):99-111.
71. Bell MD, Lysaker PH, Milstein RM, Beam-Goulet JL. Concurrent validity of the cognitive component of schizophrenia: relationship of PANSS scores to neuropsychological assessments. Psychiatry Res. 1994;54(1):51-58.
72. D'Souza DC. Cannabinoids and psychosis. Int Rev Neurobiol. 2007;78:289-326.
73. Koethe D, Gerth CW, Neatby MA, et al. Disturbances of visual information processing in early states of psychosis and experimental delta-9- tetrahydrocannabinol altered states of consciousness. Schizophr Res. 2006;88(1-3):142-150.
74. D'Souza DC, Abi-Saab WM, Madonick S, et al. Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol Psychiatry. 2005;57(6):594-608.
75. Henquet C, Rosa A, Krabbendam L, et al. An experimental study of catechol-o-methyltransferase Val158Met moderation of delta-9- tetrahydrocannabinol-induced effects on psychosis and cognition. Neuropsychopharmacology. 2006;31(12):2748-2757.
76. Cooper ZD, Haney M. Comparison of the subjective, pharmacokinetic and physiologic effects of marijuana smoked as joints and blunts. Drug Alcohol Depend. In press.
77. George TP, Vessicchio JC, Termine A, et al. Effects of smoking abstinence on visuospatial working memory function in schizophrenia. Neuropsychopharmacology. 2002;26(1):75-85.
78. McGlashan TH, Miller TJ, Woods SW, Hoffman RE, Davidson L, eds. Instrument for the Assessment of Prodromal Symptoms and States. Amsterdam, Netherlands: Kluwer Academic Publishers; 2001.
79. Verdoux H, Husky M, Tournier M, Sorbara F, Swendsen JD. Social environments and daily life occurrence of psychotic symptoms-an experience sampling test in a non-clinical population. Soc Psychiatry Psychiatr Epidemiol. 2003;38(11):654-661.